This month, an oral hearing in the US concerning the respective notices of appeal of Samsung Bioepis and Formycon is set to take place in litigation over their biosimilars to Regeneron’s Eylea (aflibercept).
On separate dates in June, a US district court in West Virginia, where all aflibercept-related litigation is currently playing out, granted the originator’s motions for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?